Biliary Atresia: From Early Symptoms to the Kasai Procedure

Biliary atresia is a disease of newborns in which the bile ducts outside the liver become inflamed, scarred, and eventually blocked, trapping bile inside the liver and causing progressive damage. It affects roughly 1 in 10,000 to 1 in 15,000 live births worldwide, making it the most common reason for pediatric liver transplantation. Without treatment, the condition is fatal within the first two years of life. With timely surgery and ongoing care, though, many children survive into adulthood with their own liver, and transplantation offers a strong safety net when the initial operation falls short.

What Happens Inside the Liver

In a healthy newborn, bile produced by the liver flows through a network of ducts into the intestine, where it helps digest fats and absorb certain vitamins. In biliary atresia, those extrahepatic bile ducts are progressively destroyed. Bile backs up into the liver, damaging liver cells and triggering fibrosis. Left unchecked, this fibrosis advances to cirrhosis.

The destruction appears to begin with some kind of initial injury to the cells lining the bile ducts. That injury alters the surface of the cells, prompting the immune system to treat them as foreign. Immune cells then mount an inflammatory attack: macrophages present the altered proteins to T cells, which release inflammatory signals and recruit more immune cells that damage the duct lining further, leading to scarring and obliteration of the ducts.¹ Several features of a newborn’s biology make this cascade more likely: the neonatal immune system has a built-in bias toward inflammation, and the newborn bile ducts lack some of the protective structural features found in older children and adults.²

What Triggers It

No single cause has been pinned down, and that frustrates both families and researchers. The leading hypothesis involves viruses, particularly rotavirus. In mouse models, infecting newborn pups with a specific strain of rotavirus produces a disease that closely mirrors human biliary atresia, complete with bile duct obstruction, duct proliferation, and liver inflammation progressing to fibrosis.³ Rotavirus can spread beyond the gut during intestinal infections in humans, and studies suggest that when it reaches the bile duct lining, it can set off the inflammatory chain reaction that leads to obstruction.⁴ Other viruses, including cytomegalovirus and reovirus, have also been implicated, but the evidence is strongest for rotavirus in animal models.

When viruses infect the bile duct lining, the infected cells release a burst of inflammatory molecules that attract immune cells including natural killer cells, neutrophils, and macrophages.⁵ The immune response itself may do more lasting damage than the virus. In one telling experiment, mice genetically engineered to lack B cells were infected with the same rotavirus strain. They carried similar levels of virus in their livers, but the inflammatory bile duct obstruction that defines biliary atresia did not develop, and their disease-free survival was dramatically higher.⁶ The implication is stark: the immune system’s overreaction, not the virus alone, drives the destruction.

Not every child who gets rotavirus develops biliary atresia, of course. In fact, almost none of them do. This is where genetics and maternal biology come in. A subset of children with biliary atresia also have spleen malformations, heart defects, or other anomalies suggesting that something went wrong during embryonic development of the bile ducts. This form, sometimes called biliary atresia splenic malformation syndrome, has been linked to rare variants in a gene called PKD1L1, which plays a role in determining left-right body symmetry and in the function of tiny hair-like structures on bile duct cells called cilia.⁷ Separately, researchers have found maternal cells residing in the livers of some children with biliary atresia, a phenomenon called maternal microchimerism. Whether these maternal cells contribute to the bile duct injury or are simply bystanders remains an open question.⁸

Recognizing It Early

The classic warning signs are persistent jaundice beyond the first two weeks of life, pale or clay-colored stools, and dark urine. The trouble is that jaundice is extremely common in healthy newborns, so it takes a sharp eye to distinguish the harmless kind from the kind that signals a blocked bile system. Many parents are told that mild jaundice is normal and will resolve on its own, which it usually does. But in biliary atresia the yellow tinge does not fade, and the stool gradually loses its color as bile stops reaching the gut.

Several countries now use stool color cards as a simple screening tool. Parents are given a card showing a range of stool colors and asked to compare their newborn’s stool against it during the first month of life. In Taiwan, implementing this screening nationwide brought earlier hospital referrals and increased the proportion of babies who had surgery within the critical early window.⁹ A study in Bangladesh found the cards had about 83% sensitivity and 79% specificity over three consecutive days of use, making them a practical, low-cost tool for resource-limited settings.¹⁰ No card catches every case, but they raise awareness among both parents and doctors.

How the Diagnosis Is Confirmed

When biliary atresia is suspected, doctors rely on a combination of blood tests, imaging, and sometimes liver biopsy. Ultrasound is usually the first imaging step. One reliable sign on ultrasound is the “triangular cord sign,” a bright, triangular-shaped area just in front of the main branch of the portal vein that corresponds to the fibrous remnant of the destroyed bile duct. Using a thickness cutoff of 4 mm for this sign, one study found 80% sensitivity and 98% specificity for distinguishing biliary atresia from neonatal hepatitis.¹¹ Another study reported that every infant in whom the sign was identified turned out to have biliary atresia confirmed at surgery.¹²

Liver biopsy can show patterns of duct damage and inflammation that point toward biliary atresia, and nuclear medicine scans can assess whether bile is reaching the intestine. One comparison found the triangular cord sign on ultrasound had 85% sensitivity and 100% specificity, while liver biopsy had 90% sensitivity and 96% specificity.¹³ In practice, centers often use a combination of these tools, and the definitive diagnosis usually comes at the time of surgery when the surgeon can directly see the bile ducts.

A newer approach involves a blood test for a protein called MMP-7 (matrix metalloproteinase-7), which is released by damaged bile duct cells. In a large North American study, MMP-7 distinguished biliary atresia from other causes of newborn jaundice with about 94% sensitivity and 78% specificity.¹⁴ A smaller study reported even higher accuracy, with sensitivity and specificity both above 94%.¹⁵ If these numbers hold up across diverse populations, MMP-7 could eventually become a routine part of the diagnostic workup, potentially shaving days off the timeline between suspicion and surgery.

The Kasai Procedure and Why Timing Matters

The first-line treatment for biliary atresia is the Kasai portoenterostomy, named after the Japanese surgeon who developed it. The surgeon removes the damaged bile ducts and connects a loop of intestine directly to the liver’s surface where the bile ducts emerge. This creates a new path for bile to drain. The operation does not cure the underlying disease, but when it works, it can restore bile flow and buy years, sometimes decades, of life with the child’s own liver.

Timing is critical. A meta-analysis found that children who had the Kasai procedure within the first 30 days of life had significantly better native liver survival at 5, 10, and 20 years compared with those who had surgery later. The risk of needing a transplant roughly doubled in the later-surgery group.¹⁶ Reviews of the literature consistently show no benefit to delaying surgery, and the consensus is to operate as early as possible.¹⁷ This is why screening efforts like the stool color card matter so much: every day gained before surgery translates into a better chance for the child’s liver.

After Surgery

Even after a successful Kasai procedure, these children need close, ongoing medical care. One common postoperative approach includes ursodeoxycholic acid (a medication that promotes bile flow) and a course of steroids. A meta-analysis found that this combination significantly lowered rates of persistent jaundice after surgery compared to controls.¹⁸ An earlier study suggested that adding intravenous antibiotics to this regimen could further accelerate jaundice clearance and reduce the need for early transplantation.¹⁹

Cholangitis, an infection of the bile ducts, is the most common complication after the Kasai procedure. Bacteria from the intestine can travel retrograde up the surgically created pathway and into the liver. Surgical techniques that incorporate an anti-reflux valve in the intestinal loop appear to reduce this risk by narrowing the pathway and making it harder for intestinal contents to wash back up.²⁰ As for preventive antibiotics, the evidence is mixed. One study found that trimethoprim-sulfamethoxazole or neomycin reduced cholangitis recurrence,²¹ but a more recent meta-analysis concluded that the overall evidence does not clearly support routine prophylactic antibiotics for all patients.²² Practice varies widely between centers, and the decision typically depends on the individual child’s risk profile.

Portal Hypertension

Even when the Kasai procedure successfully restores bile flow, the liver may still accumulate fibrosis over the years, and that scarring can raise pressure in the portal vein, the main vessel that carries blood from the intestines to the liver. This is called portal hypertension, and it can lead to enlarged veins in the esophagus or stomach (varices), an enlarged spleen, and low blood cell counts. A large Japanese registry study found that portal hypertension developed in about 46% of all biliary atresia patients, with varices occurring in roughly a third and an enlarged, overactive spleen in a similar proportion.²³ Because these complications can develop even after a technically successful surgery, children with biliary atresia need long-term monitoring, including periodic endoscopy to check for varices.²⁴

Nutritional Challenges

Bile is essential for absorbing dietary fat and fat-soluble vitamins (A, D, E, and K). When bile flow is disrupted, even partially, these nutrients are poorly absorbed. Vitamin D deficiency is the most common and potentially the most damaging, because it impairs bone growth in a period when the skeleton is developing rapidly. One study found that the majority of children with biliary atresia had radiographic signs of bone disease, with roughly 18% showing pure bone-softening and another 59% showing a combination of bone-softening and bone-thinning.²⁵ These deficiencies persist even in children whose surgery restores bile drainage, meaning long-term vitamin supplementation is often necessary, especially for children whose jaundice does not fully resolve.²⁶

Calorie needs are also elevated in these children because the liver is working harder and chronic inflammation increases energy expenditure. Most pediatric hepatology centers recommend calorie-dense formulas with medium-chain triglycerides, which are absorbed more easily without bile, and regular monitoring of growth parameters.

When Transplantation Becomes Necessary

Despite the best surgical and medical management, a substantial number of children with biliary atresia will eventually need a liver transplant. The Kasai procedure fails to restore adequate bile flow in some children entirely, and in others the liver slowly deteriorates over years due to ongoing fibrosis. Biliary atresia remains the single most common indication for pediatric liver transplantation worldwide.

The outcomes after transplant are encouraging. In a study of living-donor liver transplantation, the ten-year graft survival rate for children with biliary atresia was 94%, and it was highest among children who received their transplant before age 12 (95% to 96% graft survival at ten years). Children who underwent transplantation at age 12 or older had somewhat lower graft survival, around 84%, underscoring the importance of not waiting too long when the native liver is clearly failing.²⁷ The most common reason for graft failure was late-onset rejection that proved resistant to treatment, and nearly all of those patients were successfully re-transplanted.

Growing Up With a Native Liver

For children who clear their jaundice after the Kasai procedure and avoid transplantation, the long-term picture is surprisingly good. A follow-up study of over 150 native-liver survivors found that about two-thirds were jaundice-free at their most recent visit. Nearly all had normal blood-clotting times and albumin levels, indicating that their liver was handling its synthetic work well. Children’s growth was normal, with median weight and height sitting comfortably in the middle of the healthy range, and adults had a healthy median body mass index.²⁸ These findings are reassuring, but “native liver survivor” does not mean “cured.” Ongoing surveillance for portal hypertension, cholangitis, and nutritional deficiencies is a lifelong commitment.

Quality of Life and Caregiver Wellbeing

Living with biliary atresia affects more than just the child’s liver. Children who have been treated for the condition score lower on measures of physical health, emotional wellbeing, social functioning, and cognitive development compared to their healthy peers. The presence of co-existing medical conditions makes this gap larger.²⁹ Parents carry a burden too. A prospective study found that mothers reported significantly higher anxiety levels during and shortly after the initial surgery, and this elevated anxiety persisted at a lower level even when the child was two to three years old. Fathers’ anxiety, by contrast, did not differ significantly from the general population.³⁰ Connecting families with peer support groups and mental health resources early in the process can make a meaningful difference.

Access Gaps Around the World

Biliary atresia is a disease where geography shapes destiny. In well-resourced countries, the pathway from screening to Kasai procedure to transplant referral is well established. In low- and middle-income countries, timely diagnosis remains a challenge, and liver transplantation is rarely accessible.³¹ A child born with biliary atresia in sub-Saharan Africa or parts of South Asia may never be diagnosed, or may be diagnosed too late for the Kasai procedure to help, and transplantation is simply not available in many of these settings. Stool color card screening, training of community health workers, and investment in pediatric surgical capacity are areas where relatively modest interventions could save lives.

The Research Frontier

The rotavirus mouse model remains the workhorse of biliary atresia research. Different rotavirus strains produce different degrees of disease in mice, because certain strains target bile duct lining cells more aggressively than others.³² By manipulating both the virus and the host’s immune system, researchers are mapping out which immune pathways are essential for duct destruction and which might be safely interrupted. The B-cell experiment mentioned earlier is one example; other labs are exploring whether blocking specific inflammatory signals early could halt the cascade before permanent scarring occurs.

On the drug development side, one class of medications called IBAT inhibitors is generating cautious optimism. These drugs block the reabsorption of bile acids in the intestine, lowering the overall bile acid load in the body. The idea is that reducing circulating bile acids might limit the inflammation and fibrosis that drive liver remodeling in biliary atresia. Odevixibat, one such inhibitor, is being studied specifically in children with biliary atresia. While the drug would not replace surgery, it could become an additional tool for slowing disease progression after the Kasai procedure, particularly in children who still have elevated bile acid levels despite restored bile flow.³³ Early results are preliminary, and surgery remains the essential first step regardless.

Researchers are also probing genetics more deeply, searching for variants that might explain why the disease occurs in some newborns and not others. The discovery of PKD1L1 variants in children with the splenic malformation form of biliary atresia was one such advance, but the isolated, non-syndromic form that accounts for most cases remains genetically opaque. Whole-exome and whole-genome sequencing studies are underway in several international cohorts, and the hope is that identifying susceptibility genes might eventually enable earlier risk stratification or even preventive strategies.